EP4385523A1 — Lipid-based topical injection formulations
Assigned to Metis Techbio Co Ltd · Expires 2024-06-19 · 2y expired
What this patent protects
The present disclosure relates to a lipid-based topical injection formulation comprising a Long-Acting SusTained delivering lipid, a structured lipid, a polymer-conjugated lipid and an ionizable lipid, and optionally a neutral phospholipid. The lipid-based topical injection formu…
USPTO Abstract
The present disclosure relates to a lipid-based topical injection formulation comprising a Long-Acting SusTained delivering lipid, a structured lipid, a polymer-conjugated lipid and an ionizable lipid, and optionally a neutral phospholipid. The lipid-based topical injection formulation enables enriched delivery of drugs at an injection site and efficient expression of proteins for a prolonged period of time. The present disclosure also relates to a method of preparing the lipid-based topical injection formulation, and use of the lipid-based topical injection formulation in the delivery of biologically active substances such as nucleic acids (e.g., mRNA, miRNA, siRNA, saRNA, ASO, DNA, etc.).
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.